A gene transfer strategy for making bone marrow cells resistant to trimetrexate

Blood

Volumn 87, Issue 6, 1996, Pages 2579-2587

  Spencer, H Trent ^a   Sleep, Susan E H ^a   Rehg, J E ^a   Blakley, Raymond L ^a   Sorrentino, Brian P ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; DIHYDROFOLATE REDUCTASE; HEXADIMETHRINE BROMIDE; INTERLEUKIN 3; INTERLEUKIN 6; LEUCINE; METHOTREXATE; MUTANT PROTEIN; TRIMETREXATE; TYROSINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESISTANCE; GENE TRANSFER; HEMATOPOIETIC STEM CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEUTROPENIA; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; RETROVIRUS;

EID: 0029865455     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.6.2579.bloodjournal8762579     Document Type: Article

References (45)

1. Blakley RL: Folates and pterins, in Blakley RL, Benkovic SJ (eds): Chemistry and Biochemistry of Folates New York, NY, Wiley, 1984, p 191
2. Fry DW, Besserer JA: Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates. Cancer Res 48:6986, 1988
3. Lacerda JF, Goker E, Kheradpour A, Dennig D, Elisseyeff Y, Jagiello C, O'Reilly RJ, Bertino JR. Selective treatment of SCIDmice bearing methotrexate-transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection. Blood 85:2675, 1995
4. Witte RS, Elson P, Khandakar J, Trump DL: An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma Cancer 73:688, 1994
5. Kheradpour A, Berman E, Goker E, Lin JT, Tong WP, Bertino JR: A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia. Cancer Invest 13:36, 1995
6. Witte RS, Yeap BY, Trump DL: Trimetrexate in advanced hormone-refractory prostate cancer. An ECOG phase II trial. Invest New Drugs 12:255, 1994
7. Pappo AS, Vats T, Williams TE, Bernstein M, Kamen BA: Phase I trial of trimetrexate in pediatric solid tumors: A Pediatric Oncology Group study. Med Pediatr Oncol 21:280, 1993
8. Sirotnak FM, Moccio DM, Dorick DM: Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res 38:345, 1978
9. Browman GP, Goodyear MD, Levine MN, Russell R, Archibald SD, Young JE: Modulation of the and tumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: A randomized placebo-controlled clinical trial. J Clin Oncol 8:203, 1990
10. Ackland SP, Schilsky RL: High-dose methotrexate: A critical reappraisal. J Clin Oncol 5:2017, 1987
11. Kamen BA, Weitman SD: High-dose methotrexate: Is it warranted? Pediatr Hematol Oncol 11:135, 1994
12. Corey CA, DeSilva AD, Holland CA, Williams DA: Serial transplantation of methotrexate-resistant bone marrow: Protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 75:337, 1990
13. Williams DA, Hsieh K, DeSilva A, Mulligan RC: Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow J Exp Med 166:210, 1987
14. Li MX, Banerjee D, Zhao SC, Schweitzer BI, Mineishi S, Gilboa E, Bertino JR. Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. Blood 83:3403, 1994
15. Zhao SC, Li MX, Banerjee D, Schweitzer BI, Mineishi S, Gilboa E, Bertino JR: Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Therapy 1:27, 1994
16. Simonsen CC, Levinson AD: Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc Natl Acad Sci USA 80:2495, 1983
17. Banerjee D, Schweitzer BI, Volkenandt M, Li MX, Waltham M, Mineishi S, Zhao SC, Bertino JR: Transfection with a cDNA encoding a Ser31 or Ser34 mutant human dihydrofolate reductase into Chinese hamster ovary and mouse marrow progenitor cells confers methotrexate resistance. Gene 139:269, 1994
18. Yu M, Melera PW: Allelic variation in the dihydrofolate reductase gene at amino acid position 95 contributes to antifolate resistance in Chinese hamster cells. Cancer Res 53:6031, 1993
19. Hussain A, Lewis D, Yu M, Melera PW: Construction of a dominant selectable marker using a novel dihydrofolate reductase Gene 112:179, 1992
20. Morris JA, McIvor RS: Saturation mutagenesis at dihydrofolate reductase codons 22 and 31. A variety of amino acid substitutions conferring methotrexate resistance. Biochem Pharmacol 47:1207, 1994
21. Dicker AP, Volkenandt M, Schweitzer BI, Banerjee D, Bertino JR: Identification and characterization of a mutation in the dihydrofolate reductase gene from the methotrexate-resistant Chinese hamster ovary cell line Pro-3 MtxRIII. J Biol Chem 265:8317, 1990
22. Chunduru SK, Cody V, Luft JR, Pangborn W, Appleman JR, Blakley RL: Methotrexate-resistant variants of human dihydrofolate reductase. Effects of Phe31 substitutions. J Biol Chem 269:9547, 1994
23. Lewis WS, Cody V, Galitsky N, Luft JR, Pangborn W, Chunduru SK, Spencer HT, Appleman JR, Blakley RL: Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers. J Biol Chem 270:5057, 1995
24. Schweitzer BI, Srimatkandada S, Gritsman H, Sheridan R, Venkataraghavan R, Bertino JR: Probing the role of two hydrophobic active site residues in the human dihydrofolate reductase by site-directed mutagenesis. J Biol Chem 264:20786, 1989
25. Nakano T, Spencer HT, Appleman JR, Blakley RL: Critical role of phenylalanine 34 of human dihydrofolate reductase in substrate and inhibitor binding and in catalysis. Biochemistry 33:9945, 1994
26. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC: A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85:4486, 1988
27. Margosiak SA, Appleman JR, Santi DV, Blakley RL: Dihydrofolate reductase from the pathogenic fungus Pneumocystis carinii: Catalytic properties and interaction with antifolates. Arch Biochem Biophys 305:499, 1993
28. Miller AD, Buttimore C: Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 6:2895, 1986
29. Markowitz D, Goff S, Bank A: A safe packaging line for gene transfer: Separating viral genes on two different plasmids. J Virol 62:1120, 1988
30. Bodine DM, Karlsson S, Nienhuis AW: Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells. Proc Natl Acad Sci USA 86:8897, 1989
31. Bodine DM, McDonagh KT, Seidel NE, Nienhuis AW: Survival and retrovirus infection of murine hematopoietic stem cells in vitro: Effects of 5-FU and method of infection. Exp Hematol 19:206, 1991
32. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257:99, 1992
33. Sorrentino BP, McDonagh KT, Woods D, Orlic D: Expression of retroviral vectors containing the human MDR1 cDNA in hematopoietic cells of transplanted mice. Blood 86:491, 1995
34. Deisseroth AB, Kavanagh J, Champlin R: Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: A pilot trial. Hum Gene Trier 5:1507, 1994
35. Hesdorffer C, Antman K, Bank A, Fetell M, Mears G, Begg M: Human MDR gene transfer in patients with advanced cancer. Hum Gene Ther 5:1151, 1994
36. O'Shaughnessy JA, Cowan KH, Nienhuis AW, McDonagh KT, Sorrentino BP, Dunbar CE, Chiang Y, Wilson W, Goldspiel B, Kohler D, Cotter-Fox M, Leitman S, Gottesman M, Pastern I, Denicoff A, Noone M, Gress R: Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum Gene Ther 5:891, 1994
37. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter C, Berenson R, Brown S, Moen RC, Greenblatt J, Stewart FM, Leitman SF, Wilson WH, Cowan K, Young NS, Nienhuis AW: Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 85:3048, 1995
38. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle JN: Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 342:1134, 1993
39. Flasshove M, Banerjee D, Mineishi S, Li MX, Bertino JR, Moore MA: Ex vivo expansion and selection of human CD34+ peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. Blood 85:566, 1995
40. Podda S, Ward M, Himelstein A, Richardson C, de la Flor-Weiss E, Smith L, Gottesman M, Pastan I, Bank A: Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 89:9676, 1992
41. Moritz T, Mackay W, Glassner BJ, Williams DA, Samson L: Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo. Cancer Res 55:2608, 1995
42. May C, Gunther R, McIvor, RS: Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood 86:2439, 1995
43. Appleman JR, Beard WA, Delcamp TJ, Prendergast NJ, Freisheim JH, Blakley RL: Unusual transient- and steady-state kinetic behavior is predicted by the kinetic scheme operational for recombinant human dihydrofolate reductase. J Biol Chem 265:2740, 1990
44. Appleman JR, Prendergast N, Delcamp TJ, Freisheim JH, Blakley RL: Kinetics of the formation and isomerization of methotrexate complexes of recombinant human dihydrofolate reductase. J Biol Chem 263:10304, 1988
45. Spencer HT, Sorrentino BP, Pui C, Chunduru SK, Sleep SEH, Blakley RL: Mutations in the gene for human dihydrofolate reductase: An infrequent cause of clinical relapse in pediatric leukemia after therapy with methotrexate. Leukemia (in press)